Catalyst Wire Dossier Catalyst Wire Dossier

Daclizumab High Yield Process (DAC HYP)

daclizumab · Biogen (with AbbVie)
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Daclizumab High Yield Process (DAC HYP), covering 2016-07-11 to 2016-08-30. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis [Phase 2]

See pricing